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Summary
Background and objectives Patients with the hereditary disease Alport syndrome commonly require renal
replacement therapy (RRT) in the second or third decade of life. This study compared age at onset of RRT, renal
allograft, and patient survival in men with Alport syndrome receiving various forms of RRT (peritoneal dialysis,
hemodialysis, or transplantation) with those of men with other renal diseases.
Design, setting, participants, & measurements Patients with Alport syndrome receiving RRT identified from 14
registries in Europe were matched to patients with other renal diseases. A linear spline model was used to detect
changes in the age at start of RRT over time. Kaplan-Meier method and Cox regression analysis were used to
examine patient and graft survival.
ResultsAge at start of RRT among patients withAlport syndrome remained stable during the 1990s but increased
by 6 years between 2000–2004 and 2005–2009. Survival of patients with Alport syndrome requiring dialysis or
transplantation did not change between 1990 and 2009.However, patientswithAlport syndrome had better renal
graft and patient survival than matched controls. Numbers of living-donor transplantations were lower in
patients with Alport syndrome than in matched controls.
Conclusions These data suggest that kidney failure in patients with Alport syndrome is now being delayed
compared with previous decades. These patients appear to have superior patient survival while undergoing
dialysis and superior patient and graft survival after deceased-donor kidney transplantation compared with
patients receiving RRT because of other causes of kidney failure.
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Introduction
Alport syndrome is a hereditary nephropathy char-
acterized by progressive renal failure, sensorineural
deafness, and typical ocular abnormalities. It almost
inevitably leads to ESRD during adolescence or early
adulthood (1–3). The disease is caused by mutations
in type IV collagen genes (1,4–6). Eighty-five percent
of Alport families have an X-linked (COL4A5 gene)
and 15% an autosomal-recessive (COL4A3 or COL4A4
genes) pattern of inheritance (1,7–10). Female hetero-
zygous X-linked Alport carriers show a large inter-
and intrafamilial variability of the clinical course
and a more favorable prognosis (11,12). Heterozy-
gous COL4A3/COL4A4 carriers develop thin base-
ment membrane nephropathy (10,12,13), which may
lead to an increased risk for developing progressive
CKD (12). Thin basement membrane nephropathy is
very common, with a prevalence ranging from 1% in
the general population (13) to 5.2% in a series of trans-
plant biopsies (14). This high prevalence of heterozy-
gous carriers among family members might affect the
rate of living kidney donation in Alport families.
Patients with Alport syndrome who undergo kid-
ney transplantation typically have a good outcome
(15). However, 2%–5% of males develop anti–glomer-
ular basement (GBM) membrane disease early in the
post-transplant period, resulting in rapid loss of the
allograft (16–18). Anti-GBM disease can recur earlier
and behave more aggressively in subsequent trans-
plants. Until the late 1990s, no therapy could be of-
fered to patients with Alport syndrome to delay onset
of kidney failure. Angiotensin-converting enzyme in-
hibitor therapy may delay disease progression, ac-
cording to studies in both animal models (19) and
humans (20).
Data on patients with Alport syndrome undergoing
renal replacement therapy (RRT) are scarce. Therefore,
this study was launched to evaluate outcome of male
patients with Alport syndrome receiving RRT using
data collected by the European Renal Association-
European Dialysis and Transplant Association (ERA-
EDTA) Registry (21). The study examines the time
trends in age at onset of RRT of patients with Alport
syndrome from 1990 to 2009 and compares the
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following outcomes among patients with Alport syn-
drome and matched controls with other renal diseases:
overall patient survival during RRT, patient survival dur-
ing dialysis, and patient and graft survival after renal
transplantation.
Material and Methods
Data Collection
The ERA-EDTA Registry annually collects data on
patients who start RRT and are listed in national and
regional renal registries in Europe. Fourteen national or
regional renal registries from 11 countries, which sub-
mitted individual patient data to the ERA-EDTA Registry
from 1990 to 2009, participated in the study. These included
the national registries of Austria, Denmark, Finland,
Greece, Iceland, Norway, Sweden (from 1991), the Nether-
lands, and Scotland and the regional registries of Calabria
in Italy (from 1997) and Andalusia (Basque country, from
1992), Catalonia, and Valencian Community (from 1992) in
Spain. These registries report to cover almost 100% of the
general population in their country. Moreover, after data
are received, they are extensively checked within the ERA-
EDTA registry (21). Further details of the ERA-EDTA da-
tabase and the methods used to collect and process data
have been previously reported (22).
Cases included only male patients with ESRD due to
Alport syndrome (code 51, defined as Alport’s syndrome/
hereditary nephritis with nerve deafness) who started RRT
between January 1, 1990, and December 31, 2009, and were
still alive at day 91 after start of RRT. Females with Alport
syndrome (code 51) were excluded to avoid the inclusion
of heterozygous female carriers of X-linked Alport syn-
drome, who have a different prognosis. As shown in Table
1, controls included males undergoing RRT with ESRD
due to causes other than Alport syndrome, who were still
alive at day 91 after start of RRT. They were matched for
age (per year), year at onset of RRT (within 2 years), and
RRT modality at day 91 after onset of RRT (hemodialysis,
peritoneal dialysis, and kidney transplantation). For each
Alport case, five male controls were randomly selected
from the same age, year, and modality categories. To com-
pare survival after the first kidney transplant, a second
cohort was composed of male patients with ESRD due to
Alport syndrome who received a kidney transplant be-
tween January 1, 1990, and December 31, 2009. For each of
these Alport patients, five male controls with other causes
of ESRD were randomly selected from the same age at
transplantation (per year), year of transplantation (within
2 years), and donor kidney (living, deceased, and un-
known) categories.
Statistical Analyses
Differences in patient characteristics between groups
were examined using the chi-squared test. To detect points
in time when the age at start of RRT increased more
rapidly, a linear spline model was developed and fitted
using the Transreg procedure in SAS software, version 9.2
(SAS Institute, Inc., Cary, NC). Here the dependent variable
was the age at onset of RRT, and the spline transformation
of the year of RRT initiation was the independent variable.
The Kaplan-Meier method and Cox regression analyses
were used to compare survival probabilities. Patients were
followed until December 31, 2009. For the analysis of
patient survival on RRT, the day at start of RRT was taken
as the starting point, and the event studied was death.
Reasons for censoring were recovery of renal function, loss
to follow-up, and end of follow-up time. For the analysis of
patient survival on dialysis, the first day on dialysis was the
starting point, the event was death, and reasons for
censoring were recovery of renal function, loss to follow-
up, end of follow-up time, and renal transplantation. To
account for renal transplantation as a competing risk for
death while patients are undergoing dialysis, a competing
risk analysis was also performed. For the analysis of patient
and graft survival after transplantation, survival times
were measured from the date of the first renal trans-
plantation. The event of interest was death in patient
survival analysis and graft failure or death in graft survival
analysis. Reasons for censoring were loss to follow-up and
end of follow-up time. For all models, interactions between
Alport syndrome and the age at start of RRT, or the age at
kidney transplantation, were examined to determine
whether the association of Alport syndrome with outcome
differed between younger and older patients.
Results
Between January 1, 1990, and December 31, 2009, 456
patients with ESRD due to Alport syndrome started RRT. A
total of 2280 matched controls were included. Table 1 de-
scribes the characteristics of the patients with Alport syn-
drome and the matched controls.
Age at Start of RRT
Figure 1 shows the distribution of the age at onset of
RRT during the periods 1990–1994, 1995–1999, 2000–2004,
and 2005–2009. In the first decade of the study period, the
distribution of age remained similar and the median age
did not change. Compared with the first two periods, the
median age at the onset of RRT increased by about 1 year
during the period 2000–2004. In the most recent period,
2005–2009, a clear shift toward older ages occurred, as is
illustrated by the increase in the median age by more than
6 years compared with the period 2000–2004. The linear
spline model (Figure 2) identified the year 2000 (P=0.004)
as the time point at which the mean age at initiation of
RRT began to increase more rapidly.
Patient Survival on RRT
The total follow-up time of the 456 Alport patients was
3179 years; 38 patients died within the study period (1.20
deaths per 100 patient-years). The 2280 matched controls
had a total follow-up time of 14,746 years, and 405 patients
died (2.75 deaths per 100 patient-years). Only four (0.9%) of
the Alport patients and 21 (1.1%) of the controls were
censored because of loss to follow-up. Survival of patients
with Alport syndrome was better than for the matched
controls (Figure 3A and Table 2; P,0.001). The distribution
of causes of death did not differ significantly between the
two groups (Table 3), with cardiovascular disease and in-
fections being the most common causes. Although we
found a statistically significant interaction between Alport
syndrome as primary renal disease and the age at start of
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RRT (P=0.026), the survival advantage of patients with
Alport syndrome compared with matched controls was
consistent in both younger and older patients starting
RRT (Figure 3B and Table 2). In addition, when stratified
by period of RRT initiation, patients with Alport syndrome
showed superior survival in both 1990–1999 and 2000–
2009 (Figure 3C and Table 2). However, in neither group
was there a statistically significant difference in patient
survival between patients who started RRT in 2000–2009
and those who started it in 1990–1999 (Figure 3C; Alport
patients: hazard ratio [HR] for 2000–2009, 0.76 [95% con-
fidence interval [CI], 0.35–1.67], P=0.498; matched con-
trols: hazard ratio for 2000–2009, 0.79 [95% CI, 0.63–
1.01], P=0.057; data adjusted for differences in age over
time).
Patient Survival during Dialysis
At day 91 after the start of RRT, 395 of the 456 patients
with Alport disease were receiving dialysis (hemodialysis,
264; peritoneal dialysis, 131) (Table 1). Survival of patients
with Alport syndrome during dialysis was superior to that
of matched controls, for both hemodialysis and peritoneal
dialysis (Figure 4 and Table 2). Of 131 Alport patients re-
ceiving peritoneal dialysis who were included in the anal-
ysis, only 2 died, compared with 91 of 655 matched
controls; therefore, a reliable HR could not be calculated.
Competing risk analysis with transplantation as the com-
peting event confirmed these results (P,0.001). For patient
survival with hemodialysis, we found a statistically signif-
icant interaction between Alport syndrome as primary re-
nal disease and age at start RRT (P=0.020). However, we
Table 1. Characteristics of patients with Alport syndrome and matched controls who started renal replacement therapy or received
their first kidney transplant
Patients' Characteristics Alport PatientsStarting RRT
Matched Controls
Starting RRTa
Alport Patients
Receiving
Transplant
Matched Controls
Receiving
Transplantb
Patients (n) 456 2280 408 2040
Median age at start of
RRT (yr)
27.9 (21.7–40.5) 28.0 (21.6–40.2) 25.7 (20.5–35.9) 26.3 (20.4–36.0)
Median age at first
transplant (yr)
28.0 (22.1–38.0) 27.4 (21.7–36.7) 27.9 (22.3–37.6) 27.9 (22.5–37.7)
Median year at start of
RRT
2000 (1995–2004) 2000 (1995–2004) 1998 (1993–2002) 1998 (1993–2002)
Median year of first
transplant
2003 (1998–2006) 2003 (1998–2007) 1999 (1995–2004) 2000 (1995–2005)
Treatment modality at
day 91, n (%)
Hemodialysis 264 (57.9) 1320 (57.9) 226 (56.4) 1216 (60.2)
Peritoneal dialysis 131 (28.7) 655 (28.7) 114 (28.4) 520 (25.7)
Kidney
transplantation
61 (13.4) 305 (13.4) 61 (15.2) 284 (14.1)
Primary renal disease, n (%)
Alport syndrome 456 (100) — 408 (100) —
GN/sclerosis — 685 (30.0) — 694 (34.0)
Congenital anomalies
of kidney and
urinary tract
— 377 (16.5) — 376 (18.4)
Cystic kidney disease — 168 (7.4) — 147 (7.2)
Diabetes — 278 (12.2) — 181 (8.9)
Hypertension/renal
vascular disease
— 134 (5.9) — 120 (5.9)
Multisystem diseases — 159 (7.0) — 144 (7.1)
Miscellaneous — 129 (5.7) — 105 (5.2)
Unknown/missing, — 350 (15.4) — 273 (13.4)
Median time to first
transplant (yr)
1.4 (0.6–2.7) 1.3 (0.6–2.6)
Kidney donor source, n (%) — —
Deceased donor — — 257 (63.0) 1285 (63.0)
Living donor — — 98 (24.0) 490 (24.0)
Unknown type of
donor
— — 53 (13.0) 265 (13.0)
Medians are expressed with 25th, 75th percentiles. RRT, renal replacement therapy.
aMatched for age at start of RRT, year at start of RRT (2-year period), RRT modality at day 91 (hemodialysis, peritoneal dialysis, or
transplant).
bMatched for age at first transplant, year at first transplant (2-year period), transplant donor source (deceased, living, or unknown
donor).
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found no relevant difference in outcomes for patients
younger than 25 years of age (HR, 0.61 [95% CI, 0.37–
0.99]) or 25 years of age or older (HR, 0.55 [95% CI,
0.35–0.86]) at the start of RRT.
Patient and Graft Survival after Kidney Transplantation
Between January 1, 1990, and December 31, 2009, a total
of 408 patients with Alport syndrome underwent kidney
transplantation. These patients were matched for age, year
of transplantation, and kidney donor source with 2040
kidney transplant recipients with other renal diseases. Fig-
ure 5 and Table 2 demonstrate that patients with Alport
syndrome had superior patient and graft survival. There
was no statistically significant interaction between Alport
syndrome as primary renal disease and age at kidney
transplantation for graft and patient survival after trans-
plantation. Patients with Alport syndrome received a kid-
ney from a living donor less often than did matched
controls (data not shown). Stratified analyses (Table 2) re-
vealed no statistically significant difference in patient and
graft survival between patients with Alport syndrome and
matched controls after living-donor transplantation. In
contrast, patient and graft survival were statistically sig-
nificantly better in patients with Alport syndrome after
deceased-donor transplantation (Table 2).
Discussion
To our knowledge, this is the first study to investigate the
epidemiology of ESRD due to Alport syndrome by using a
large data set from the ERA-EDTA Registry, including
individual data from European patients receiving RRT.
Several outcome measures were evaluated, including
patient survival on RRT and survival after kidney trans-
plantation as the most relevant endpoints.
Patient survival on RRT (dialysis or kidney transplan-
tation) was found to be superior for patients with Alport
syndrome compared with matched controls with other
diseases. One explanation for this superior outcome is the
absence of other essential organ system involvement; this
absence leads to less morbidity than do, for example,
diabetes and systemic inflammatory diseases that cause
kidney failure. Such inflammatory diseases, including
lupus nephritis and vasculitis, are likely to be responsible
for the inferior survival during dialysis and after kidney
transplantation (23). Further, these diseases require more
aggressive pharmacologic therapy, potentially resulting in
more severe adverse effects. In patients with congenital
anomalies of the urinary tract and kidney, ESRD may
also be associated with increased morbidity due to surgical
procedures and infectious complications, which can be
life-threatening. Patients with these and several other renal
diseases have an increased risk for serious complications
from the illness itself or adverse treatment effects, possibly
with fatal consequences. Furthermore, patients with Al-
port syndrome are thought to benefit from the nonrecur-
rent character of their disease in their kidney allografts.
Of note, patients with Alport syndrome seem to do
particularly well with peritoneal dialysis. Among these
patients, the potentially better outcome associated with
peritoneal dialysis compared with hemodialysis requires
further study. The absolute risk for death in patients with
Alport syndrome is lower than in matched controls.
However, the relative distribution of causes of death
from cardiovascular disease, infection, and suicide did
not differ between patients with Alport syndrome and
matched controls. The similar risk for death from cardio-
vascular disease is notable because previous unpublished
work suggested that patients with Alport syndrome have
an increased risk for vascular events; this elevated risk is
presumably due to a less stable architecture of their
vascular basement membranes, which lack the disulfide-
bonds of the a3/a4/a5 type IV collagen chains. This no-
tion is supported by the observation of an increased risk
for premature stroke in patients with mutations in the a1
chain type IV collagen (24).
The relatively low rate of living-donor kidney trans-
plants in patients with Alport syndrome is probably due to
the genetic cause of disease, resulting in other affected
family members and small family sizes. Nevertheless,
overall kidney graft and patient survival after kidney
transplantation were better in patients with Alport
Figure 1. | Distribution of the age and median age at onset of renal
replacement therapy (RRT) during the periods 1990–1994, 1995–
1999, 2000–2004 and 2005–2009 in patients with Alport syndrome.
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syndrome than in matched controls. However, patients
with Alport syndrome who receive a transplant run the risk
of developing post-transplant anti-GBM nephritis caused
by circulating alloantibodies against the “normal” donor-
kidney GBM containing a3/a4/a5 type IV collagen
chains. The immune system of patients with Alport syn-
drome recognizes these chains as foreign. Anti-GBM dis-
ease, which occurs in 2%–5% of patients with Alport
syndrome who receive a transplant (15–18), might contrib-
ute to a possible lack of superior graft survival in patients
with this syndrome compared with controls in the first 2
years after transplantation. In fact, the graft survival curve
begins to diverge from that of controls approximately 3
years after transplantation (Figure 5B). An overall superior
survival of patients with Alport syndrome after kidney
transplantation in general is thought to be caused by a
better preservation of general health (due to a lower bur-
den of comorbid conditions and treatment complications)
compared with patients with other underlying renal
diseases, in addition to an enhanced graft survival. The
median graft survival in 56 patients with Alport syndrome
from the European Alport registry (20) was 19 years (un-
published data). Superior graft survival can be partly ex-
plained by the nonrecurrence of the genetic kidney disease
in Alport syndrome.
It is encouraging that the age at which patients with
Alport syndrome in Europe require RRT increased slightly
starting in 2000 and has increased even more from 2005
onward (Figures 1 and 2). It is conceivable that increasing
use of renoprotective therapy with angiotensin-converting
enzyme inhibitors or angiotensin-receptor blockers over
the past two decades may have been beneficial in adoles-
cents with Alport syndrome (12,20). In addition, earlier
diagnosis and increased awareness of possible therapeutic
options for Alport syndrome in recent years may have
delayed the onset of RRT and improved outcome. Never-
theless, the data provide no evidence that the delay in
onset of RRT is due to changes in clinical practice resulting
in a later start of dialysis. Patient survival after initiation of
RRT did not change over the two different periods (1990–
1999 versus 2000–2009) in patients with Alport syndrome
or in controls.
In this study, the controls were selected from the same
age, year, and modality categories as patients with Alport
syndrome. Although it would have been preferable to
match with respect to comorbidity as well, these data were
not available. Moreover, a previous study has shown that
once age, sex, and primary renal disease are included in
models for patient survival on RRT, comorbidity may add
relatively little to the explanation of the variance in
mortality (25).
In conclusion, our data suggest that renal failure in
patients with Alport syndrome may be delayed compared
with previous decades. Patient survival with RRT did not
improve over time, suggesting that patients with Alport
syndrome may benefit most from pharmacologic treat-
ments that contribute to the postponement of ESRD.
However, the good prognosis of these patients on RRT
found in our study should be balanced against the risk-
benefit ratio of future therapies (26,27). Nevertheless, com-
pared with patients who have other renal diseases,
Figure 2. | Linear splinesmodel of the age and ofmedian age at onset
of renal replacement therapy (RRT) during 1990–2009 in patients
with Alport syndrome.
Figure 3. | Patient survival among patients with Alport syndrome receiving renal replacement therapy (RRT) compared with matched
controls. Numbers in parentheses are 95% confidence intervals. HR, hazard ratio.
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patients with Alport syndrome appear to have superior
patient survival with dialysis and superior patient and re-
nal allograft survival after deceased-donor kidney trans-
plantation.
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Table 2. Hazard ratios comparing survival of patients with Alport syndrome receiving renal replacement therapy and matched
controls
Survival Type Hazard Ratio (95% CI) P Value
Overall RRT patient survivala 0.42 (0.30–0.59) 0.000
RRT patient survival by age at start of RRTa
0–24 yra 0.37 (0.15–0.92) 0.03
$25 yra 0.43 (0.30–0.62) 0.000
RRT patient survival by perioda
1990–1999a 0.43 (0.28–0.65) 0.000
2000–2009a 0.41 (0.23–0.72) 0.002
Patient survival during dialysisa 0.48 (0.32–0.72) 0.000
Hemodialysisa 0.57 (0.37–0.87) 0.010
Peritoneal dialysisa NAb NAb
Patient survival after transplantationc 0.46 (0.29–0.74) 0.001
Deceased donord 0.51 (0.30–0.87) 0.013
Living donord 0.42 (0.10–1.79) 0.24
Graft survival after transplantationc 0.75 (0.60–0.93) 0.008
Deceased donord 0.69 (0.52–0.90) 0.007
Living donord 0.87 (0.54–1.40) 0.57
CI, confidence interval; RRT, renal replacement therapy; NA, not available.
aAdjusted for age at start of RRT and year at start of RRT.
bNumber of events too low to perform Cox regression analyses.
cAdjusted for age at transplantation, year of transplantation, and kidney donor source.
dAdjusted for age at transplantation and year of transplantation.
Table 3. Distribution of causes of death among patients with Alport syndrome and matched controls
Causes of Death Patients with AlportSyndrome (n=38)
Matched Controls
(n=405)
Chi-Squared
P Value
Cardiovascular 12 (31.6) 125 (30.9) 0.93
Infection 7 (18.4) 60 (14.8) 0.55
Suicide/treatment refusal/
withdrawal/cachexia
4 (10.5) 27 (6.7) 0.37
Malignancies 3 (7.9) 30 (7.4) 0.91
Miscellaneous 5 (13.2) 98 (24.12) 0.12
Unknown/unavailable 7 (18.4) 65 (16.1) 0.71
Values are the numbers (percentages) of patients.
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